Africa’s journey in battling devastating diseases like HIV/AIDS and malaria has been a story of resilience and hard-won progress. Yet, this progress is constantly threatened by a systemic issue that hampers access to life-saving medicines and stifles local industry: regulatory fragmentation.
The Summit was attended by, among others, Hon. Monica Musenero, the Minister for Science and Technology, Deputy Speaker Thomas Tayebwa, and Amason Jeffah Kingi, the Speaker of the Kenyan Senate.
Speaking at the Africa Health Summit, held in Kampala, Emmanuel Katongole, Co-founder and Board Chairman of Quality Chemical Industries Limited (QCIL), delivered a powerful and urgent call to action, highlighting the severe cost of regulatory divergence and positioning pharmaceutical sovereignty not as a luxury, but as the only route to true health independence.
Staggering Cost of Fragmentation
Katongole observed that although Africa is home to 54 countries, the continent currently operates 54 separate regulatory systems. “This bureaucratic nightmare means that a medicine must undergo separate, time-consuming product registrations in each country, often demanding the same data repeatedly,” Katongole said.
He detailed the critical impact of this fragmentation, noting the following:
Delayed Access: The process slows access to life-saving medicines by years.
Increased Cost: This redundancy and complexity increase medicine costs by up to 50%.
He pointed out that Africa carries 80% of the global malaria burden, yet manufactures less than 5% of its malaria medicines. This dependence, according to Katongole, creates critical vulnerability, as the recent COVID-19 pandemic made it painfully clear.
Katongole was unequivocal in his demand for immediate action, saying, “We must operationalise the African Medicines Agency not tomorrow but yesterday. We cannot keep solving African problems with imported solutions.”
Path to Pharmaceutical Sovereignty
The solution, championed by leaders like Katongole, lies in the deliberate, coordinated, and bold approach that African nations, and companies like Uganda’s QCIL, must embrace.
The establishment of the African Medicines Agency (AMA), which has been ratified by a significant number of African Union Member States, is designed to address this regulatory bottleneck.
It aims to harmonise standards and create a central, collaborative regulatory system, thereby strengthening national capacity and allowing quality-assured, affordable medicines to reach the market faster.
For Uganda, QCIL’s existence is a testament to what is possible when a nation is deliberate and bold. Katongole stressed that the company was founded on the belief that Africa must build its own manufacturing base.
Pharmaceutical sovereignty, as reiterated by Katongole, means:
Self-Sufficiency: Manufacturing essential medicines locally and reducing reliance on global supply chains that have historically disadvantaged the continent.
Economic Value: Creating high-value jobs, fostering skills development, and retaining wealth within African economies.
Health Security: Ensuring immediate access to critical treatments during pandemics or emergencies, free from geopolitical pressures.
The message from the summit is clear: Africa’s fight for health independence must now be fought in the regulatory and industrial spheres.
By operationalising the AMA and backing local manufacturers, the continent can finally turn the tide and ensure that its citizens receive the quality healthcare they deserve, without crippling delays or prohibitive costs.